# Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis

> **NCT02489227** · PHASE3 · COMPLETED · sponsor: **Coherus Oncology, Inc.** · enrollment: 545 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** CHS-1420
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT02489227
- **Lead sponsor:** Coherus Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2016-05-06
- **Final completion:** 2017-03
- **Target enrollment:** 545 (ACTUAL)
- **Last updated:** 2020-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02489227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02489227, "Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02489227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*